Amgen Worldwide
A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.
オンラインリソース
アムジェンは、患者さんが関心のある分野について学べるよう、多数のリソースを用意しております。
疾患教育
重点領域
A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.
アムジェンは、患者さんが関心のある分野について学べるよう、多数のリソースを用意しております。
アムジェン株式会社（本社：東京、代表取締役社長：スティーブ・スギノ）は、この度、株式会社MICIN（マイシン、本社：東京都千代田区、代表取締役：原聖吾、以下MICIN）と、同社が有するオンライン診療サービス「curon（クロン）」（以下、クロン）を用いた、オンラインにおける頭痛診療の検証プログラムを開始いたします。
本プログラムでは、頭痛治療を専門に行っている診療科の医療従事者と頭痛患者さんとのより良いコミュニケーション構築や効果的な問診方法、また、医療従事者と患者が、オンライン診療から対面診療と同様の治療満足度を得られるかを検証します。
現在の新型コロナウイルス感染拡大の影響を受け、オンライン診療の有用性は世界的にも注目されています。日本の頭痛治療においても、2020年4月1日から「一次性頭痛（片頭痛、緊張型頭痛、群発頭痛、三叉神経・自律神経性頭痛等）」へのオンライン診療が保険適用されています。アムジェン株式会社とMICINは、2020年7月に慢性皮膚疾患を対象に治療・服薬の利便性およびアドヒアランスの向上に関する検証プログラムを開始しており、今回、頭痛領域においても同様のプログラムを実施します。
アムジェン株式会社代表取締役社長のスティーブ・スギノは、次のように述べています。「コロナ禍において、新たな診療の在り方に対する探求は様々な場面で加速しています。2020年に実施した慢性皮膚疾患領域における検証プログラムに続き、この度もMICIN社と共に、慢性頭痛患者さんにとってのオンライン診療の価値について、新たな知見の創出に取り組めることを嬉しく思っています」
MICIN代表取締役の原聖吾は、次のように述べています。「慢性頭痛によって患者さんは、日常生活に支障をきたし、通院も負担となります。この領域の知見の深いアムジェン社とご一緒させていただき、デジタルツールなどを活用することで患者さんの負担を軽減しながら適切な治療が受けられるサポートができるよう本プログラムを進めてまいります」
オンライン診療サービス「curon（クロン）」について
クロンは株式会社 MICIN が 2016 年 4 月に提供を始めたオンライン診療サービスです。 患者はスマートフォン、医療機関はパソコンまたはタブレット端末を使用し、予約から問診、診察、 決済、処方せんや医薬品の配送⼿続きまでをオンラインで完結させることができます。クロンは 2021年1月時点で 約5,000 の医療機関に導⼊されており、全都道府県を網羅しています。
クロンのサービス紹介サイト：https://curon.co
アムジェン株式会社について
アムジェン株式会社は、世界最大規模の独立バイオテクノロジー企業である米国アムジェン社の日本法人です。2013年10月にアステラス製薬との合弁会社であるアステラス・アムジェン・バイオファーマとして事業を開始し、2020年4月1日にアムジェン社の完全子会社となり商号を変更しました。アムジェン株式会社では、循環器疾患、がん、骨疾患、炎症・免疫性疾患、神経疾患を始めとするアンメット・メディカル・ニーズが高い領域に焦点を絞り、現在約600人の従業員が、「To serve patients – 患者さんのために、今できるすべてを」というミッションのもと、臨床開発から販売までの活動を行っています。
株式会社MICIN について
株式会社MICIN（マイシン）は医師で代表取締役の原聖吾が2015年に設立しました。オンライン診療/服薬指導などを手掛けるアプリケーション事業、医薬品の臨床開発向けデジタルソリューション事業、診療・患者生活を支援するデジタルセラピューティクス事業などを展開しています。「すべての人が納得して生きて、最期を迎えられる世界を」というビジョンの実現を目指しています。
コーポレートサイト： https://micin.jp
Forward-Looking Statements (Amgen Inc.)
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company, including Adaptive Biotechnologies (including statements regarding such collaboration's ability to discover and develop fully-human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19), BeiGene, Ltd., or the Otezla acquisition, including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion, as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our business, outcomes, progress, or effects relating to studies of Otezla as a potential treatment for COVID-19, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
###
この件に関するお問い合わせ先
アムジェン株式会社（東京）
コーポレート・アフェアーズ
TEL 03-5293-9516
株式会社MICIN（マイシン）
篠原さやか
Email:pr@micin.jp